SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)
- Conditions
- Alzheimer's Disease
- Registration Number
- NCT00093951
- Lead Sponsor
- Saegis Pharmaceuticals
- Brief Summary
The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.
- Detailed Description
SGS742 is a GABA(B) receptor antagonist. It is an orally active drug and possesses neurochemical and psychopharmacologic features that suggest it could improve memory and cognition in humans. The primary objective of the SGS742 clinical trial will be to determine the effect of SGS742 on memory and cognition in individuals diagnosed with mild to moderate Alzheimer's disease. The duration of the study is 3 months with 5 clinic visits.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 280
- 55 to 90 years of age
- Diagnosed with mild to moderate Alzheimer's disease
- Willing caregiver
- In general good health
- Call 1-877-MY-MEMORY and ask to be referred to a study center located near you for entry criteria information.
Prohibited Meds:
- Alzheimer's medications (Aricept, Exelon, Remydl, Nemenda)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (42)
Dedicated Clinical Research
πΊπΈSun City, Arizona, United States
Northwest NeuroSpecialists, PLLC
πΊπΈTucson, Arizona, United States
Clinical Trials Incorporated
πΊπΈLittle Rock, Arkansas, United States
Margolin Brain Institute
πΊπΈFresno, California, United States
NervePro Research
πΊπΈIrvine, California, United States
Center for Neurologic Studies
πΊπΈLa Jolla, California, United States
Neuro Therapeutics, Inc.
πΊπΈPasadena, California, United States
Pacific Research Network, Inc.
πΊπΈSan Diego, California, United States
Affiliated Research Institute
πΊπΈSan Diego, California, United States
San Francisco Clinical Research Center
πΊπΈSan Francisco, California, United States
Scroll for more (32 remaining)Dedicated Clinical ResearchπΊπΈSun City, Arizona, United States